Home > Insider Trading > Filing (0001209191-19-027685)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875320	Vertex Pharmaceuticals Inc / Ma	VRTX	Pharmaceutical Preparations (2834)	043039129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1557290	A Stuart Arbuckle	C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210	Evp\Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-05-02	2,155	$91.05	35,395	No	4	M	Direct
Common Stock	Disposition	2019-05-02	1,198	$168.56	34,197	No	4	S	Direct
Common Stock	Disposition	2019-05-02	457	$169.31	33,740	No	4	S	Direct
Common Stock	Disposition	2019-05-02	400	$170.72	33,340	No	4	S	Direct
Common Stock	Disposition	2019-05-02	100	$171.70	33,240	No	4	S	Direct
Common Stock	Acquisiton	2019-05-03	1,553	$86.52	34,793	No	4	M	Direct
Commonstock	Disposition	2019-05-03	240	$170.28	34,553	No	4	S	Direct
Common Stock	Disposition	2019-05-03	320	$171.31	34,233	No	4	S	Direct
Common Stock	Disposition	2019-05-03	400	$172.73	33,833	No	4	S	Direct
Common Stock	Disposition	2019-05-03	593	$173.60	33,240	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2019-05-02	2,155	$0.00	2,155	$91.05
Common Stock	Stock Option (Right to Buy)	Acquisiton	2019-05-03	1,553	$0.00	1,553	$86.52

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
6,466		2026-02-01	No	4	M	Direct
10,873		2027-02-02	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	140	Indirect	401(k)

Footnotes

Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $168.56 (range $168.07 to $168.97).
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $169.31 (range $169.11 to $169.49).
Open market sales reported on this line occurred at a weighted average price of $170.72 (range $170.34 to $171.24).
Open market sales reported on this line occurred at a weighted average price of $170.28 (range $169.70 to $170.64).
Open market sales reported on this line occurred at a weighted average price of $171.31 (range $170.90 to $171.81).
Open market sales reported on this line occurred at a weighted average price of $172.73 (range $172.12 to $173.12).
Open market sales reported on this line occurred at a weighted average price of $173.60 (range $173.29 to $174.08).
The option vests in 16 quarterly installments from 02/02/2016.
The option vests in 16 quarterly installments from 02/03/2017.